N
BMY.RT

Nuveen’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Nuveen’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,700
Closed -$7K – 3434
2020
Q4 		$7K Hold
10,700
– – ﹤0.01% 3261
2020
Q3 		$24K Sell
10,700
-150,636
-93% -$430K ﹤0.01% 3249
2020
Q2 		$577K Hold
161,336
– – ﹤0.01% 2844
2020
Q1 		$613K Sell
161,336
-1,320,326
-89% -$4.35M ﹤0.01% 2701
2019
Q4 		$4.46M Buy
+1,481,662
New +$3.85M ﹤0.01% 2052

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Nuveen's BMY.RT Position: Q1 2021 in Review

Nuveen sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,700 shares — an estimated $7K sold.

Nuveen first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $4.46M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Nuveen reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Nuveen sold 10,700 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $7K.
  • Nuveen first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Nuveen's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4.46M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Nuveen's 13F filing for Q1 2021, filed 17 May 2021.